Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

# Change of Share Registry

**16 January 2025– Melbourne, Australia: Neurizon Therapeutics Limited** (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, advises that effective Monday, 20 January 2025, Neurizon's provider for shareholder registry services will change from Computershare Investor Services Pty Limited to Automic Pty Ltd ("Automic").

Our new Share registry contact details are as follows:

Automic Group
Level 12, 530 Collins Street
Melbourne VIC 3000

GPO Box 5193
Sydney NSW 2001

Neurizon's transition to Automic as its shareholder registry service provider brings enhanced convenience and functionality for shareholders. Shareholders can easily and efficiently manage their holdings via Automic's secure and highly accessible online investor portal. Automic's portal offers streamlined processes for updating personal details, accessing statements and transaction history, and voting at company meetings, ensuring a smoother and more efficient experience.

Shareholder registration online
Shareholders that are not already a user of Automic's investor portal may visit https://investor.automic.com.au and signup to register their details using the three simple steps provided in the setup process.

Shareholders with any queries in relation to their Neurizon holding are advised to contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (international).

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

**Dr. Michael Thurn**
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

**Lidija Damjanovic**
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0)425 700 504

## About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

## Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com